目次
Table of Content
1. Trispecific Antibody As Targeted Therapy
2. Trispecific Antibody - Current Clinical Development and Future Commercialization Outlook
2.1 Current Market Development Scenario
2.2 Future Market Commercialization Outlook
3. Trispecific Antibody Clinical and Market Development Trend Analysis By Region
3.1 US
3.2 China
3.3 EU
3.4 UK
3.5 Japan
3.6 Australia
4. Trispecific Antibodies Therapeutic Clinical Tends By Indications
4.1 Cancer
4.1.1 Breast Cancer
4.1.2 Colorectal Cancer
4.1.3 Lung Cancer
4.1.4 Brain Cancer
4.1.5 Multiple Myeloma
4.1.6 Lymphoma
4.1.7 Leukemia
4.2 Viral Infections
4.3 Ophthalmic Diseases
4.4 Autoimmune and Inflammatory Diseases
5. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication and Phase
5.1 Research
5.2 Preclinical
5.3 Phase I
5.4 Phase I/II
5.5 Phase II/III
6. Global Trispecific Antibody Market Dynamics
6.1 Market Drivers
6.2 Market Challenges
7. Recent Trends In Trispecific Antibody Market: Partnerships, Acquisitions, Collaboration, and Investments
8. Combinations Approaches For Bourgeoning Trispecific Antibody
8.1 Immunotherapy
8.2 Radiotherapy
9. Platforms Used For Pioneering Trispecific Antibody
9.1 Chugai Pharmaceutical - Dual-Ig Platform
9.2 Ichnos Sciences - BEAT Platform
9.3 Mab Works - Multispecific Antibody Platform
9.4 Molecular Partners - DARPin Platform
9.5 Merus - Triclonics Platform
9.6 Purple Biotech - Tribody Antibody Platform
9.7 Shine-On BioMedical - Trispecific T Cell Engager Antibody
9.8 Simcere Zaiming - T-Cell Engager Polyspecific Antibody Technology Platform
9.9 Tavotek Biotherapeutics - TavoSelect and TavoPrecise Platforms
9.10 Zymeworks - Azymetric
10. Competitive Landscape
10.1 Antibody Studio
10.2 BeiGene
10.3 Beijing Mabworks Biotech
10.4 Biocytogen Pharmaceuticals
10.5 Candid Therapeutics
10.6 Chimagen Biosciences
10.7 Chiome Bioscience
10.8 Chugai Pharmaceutical
10.9 Eluminex Biosciences
10.10 Genor Biopharma
10.11 Harpoon Therapeutics
10.12 Ichnos Glenmark Innovation
10.13 KisoJi Biotechnology
10.14 L and L Biopharma
10.15 Lyvgen Biopharma
10.16 Numab
10.17 OPKO Health
10.18 Sanofi
10.19 Shine-On
10.20 Zymeworks
List of Figures
Figure 1-1: Trispecific Antibody As Targeted Therapy
Figure 2-1: Strategies To Develop Next Generation Trispecific Antibody
Figure 2-2: Aspects Influencing Future Of Trispecific Antibody
Figure 3-1: POTENTIA Phase 1 (NCT04839991) Study - Initiation and Completion Year
Figure 3-2: SAL101JG Phase 1 Study (NCT05735366) - Initiation and Completion Year
Figure 4-1: NM32-2668 Phase 1 Study (NCT06299163) - Initiation and Completion Year
Figure 4-2: MK-6070-001/HPN328-4001 Phase 1/2 (NCT04471727) Study - Initiation and Completion Year
Figure 4-3: MK-6070-002 Phase 1/2 MK-6070-002 (NCT06780137) Study - Initiation and Completion Year
Figure 4-4: GB263T-FIH001 Phase 1/2 Study (NCT05332574) - Initiation and Completion Year
Figure 4-5: SIM0500-101 Phase 1 (NCT06375044) Study - Initiation and Completion Year
Figure 4-6: ISB 2001-101 Phase 1 (NCT05862012) Study - Initiation and Completion Year
Figure 4-7: CR109234 Phase 1 (NCT05652335) Study - Initiation and Completion Year
Figure 4-8: JNJ-79635322 Phase 1 (NCT06768489) Study - Initiation and Completion Year
Figure 4-9: Multiple Myeloma - Trispecific Antibodies With Regulatory Designations
Figure 4-10: CPIT565A12101 Phase 1 (NCT05397496) Study - Initiation and Completion Year
Figure 4-11: CR109174 Phase 1 (NCT05424822) Study - Initiation and Completion Year
Figure 4-12: JNJ-80948543 Phase 2 (NCT06660563) Study - Initiation and Completion Year
Figure 4-13: JNJ-80948543 Phase 1 (NCT06139406) Study - Initiation and Completion Year
Figure 4-14: AZD5492 Phase 1/2 (NCT06542250) Study - Initiation and Completion Year
Figure 4-15: Restoret - Structure
Figure 4-16: BRUNELLO Phase 2/3 (NCT06571045) Study - Initiation and Completion Year
Figure 4-17: Ophthalmic Diseases - Eluminex Ophthalmics Trispecific Antibody Candidates
Figure 4-18: CPIT565B12101 Phase 1 (NCT06335979) Study - Initiation and Completion Year
Figure 6-1 : Trispecific Antibody - Market Drivers
Figure 6-2: Trispecific Antibody - Market Challenges
Figure 9-1: Chugai Pharmaceutical - Dual-Ig Platform
Figure 9-2: Mab Works - Multispecific Antibody Platform
Figure 9-3: DARPin Platform - Molecular Partners
Figure 9-4: Merus - Triclonics Platform
Figure 9-5: Purple Biotech - Tribody Antibody Platform
Figure 9-6: Shine-On BioMedical - Trispecific T Cell Engager Antibody
Figure 9-7: Zymeworks Azymetric
List of Tables
Table 3-1: US - Ongoing Clinical Trials For Trispecific Antibodies
Table 3-2: EU - Ongoing Clinical Trials For Trispecific Antibodies
Table 3-3: Australia -Ongoing Clinical Trials For Trispecific Antibodies
